[An MRI for Every Patient with Back Pain?] / Jedem Rückenpatienten sein MRI?

An MRI for Every Patient with Back Pain? Abstract. Imaging in spinal disorders has changed in the past years. Improved MRI techniques allow for better image interpretation. Unchanged, however, close correlation between clinical evaluation and imaging results remains crucial for correct diagnoses and subsequent therapeutical decisions. Reimbursement cuts have made MRI more affordable in Switzerland while being widely available. This allows - if used according to guidelines - for optimal treatment of patients with spinal disorders.

Safety and effectiveness of CATCH+ as a first-line device for revascularization in the treatment of acute ischemic stroke.

PURPOSE: Mechanical thrombectomy devices and stent retrievers have recently been advocated for use as first-line therapy in acute ischemic stroke. Here we evaluate the safety and effectiveness of the CATCH+ stent retriever as a percutaneous thrombectomy device. METHODS: A retrospective analysis was performed on 101 consecutive patients who presented with anterior or posterior intracranial vessel occlusion and were treated with the CATCH+ intracranial system, either alone or in combination with intravenous tissue plasminogen activator, at a single treatment center. The primary outcome measure was successful post-procedural reperfusion as classified by the mTICI score. Secondary endpoints included mortality rate, incidence of adverse events, and functional outcomes evaluated at discharge using the mRS score. RESULTS: Sixty-nine (68.3%) patients received thrombolysis prior to mechanical thrombectomy. Successful reperfusion (mTICI≥2b) was achieved in 73.3% of patients at the end of the procedure, and good functional outcomes (mRS≤2) were observed in 32.7% of patients at discharge. Three patients developed asymptomatic subarachnoid hemorrhage, two developed asymptomatic dissections of the internal carotid artery, and one patient developed a symptomatic intracranial hemorrhage. Seventeen patients died (mortality rate 16.8%). CONCLUSIONS: The CATCH+ device is a safe and effective mechanical thrombectomy device for the first-line treatment of acute ischemic stroke.

A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis.

BACKGROUND: We report a case of progressive Granulomatosis with Polyangiitis (Wegener's Granulomatosis) with life-threatening complications of both the underlying disease and induction immunosuppressive therapy. Here, for the first time, cyclophosphamide toxicity and severe opportunistic infections including pneumocystis jirovecii- pneumonia were found in one case in a close temporal relationship. CASE PRESENTATION: A 34-year-old male patient of Caucasian ethnicity presented with acute renal failure necessitating hemodialysis treatment due to Granulomatosis with Polyangiitis (Wegener's Granulomatosis). Kidney disease progressed to end-stage renal disease shortly after first diagnosis. After the 2nd bolus of cyclophosphamide shortly, induction immunosuppression (glucocorticoid/cyclophosphamide) was interrupted for repeat infections and resumed 5 years later. By that time, the lungs developed large pulmonary cavernae most likely due to smoldering granuloma indicative for the failed goal of disease remission. Therefore, induction immunosuppression was resumed. Following two monthly boli of cyclophosphamide, the patient developed pericardial effusion and, consecutively, atrioventricular blockade most likely due to cyclophosphamide. After recovery, the patient was discharged without cotrimoxacole. 10 weeks after the last cyclophosphamide bolus and 6 weeks after cessation of cotrimoxacole, the patient was readmitted to the intensive-care unit with Pneumocystis jirovecii pneumonia, and died 6 months later or 74 months after first diagnosis of Granulomatosis with Polyangiitis. CONCLUSIONS: This case illustrates both the need for adequate immunosuppressive therapy to reach disease remission and the limitations thereof in terms of complications including cardiotoxicity of cyclophosphamide and Pneumocystis jirovecii pneumonia. In line with current recommendations, the present case strongly encourages pneumocystis jirovecii- pneumonia chemoprophylaxis for at least 6 months following induction therapy in Granulomatosis with Polyangiitis.